[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Δ9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients

[1]  J. Leckman,et al.  Tourette’s Syndrome and Tic Disorders , 2005 .

[2]  M. Nöthen,et al.  Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[3]  H. Kung,et al.  Dosimetry of iodine-123 iodobenzamide in healthy volunteers , 1993, European Journal of Nuclear Medicine.

[4]  H. Emrich,et al.  Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. , 2003, The Journal of clinical psychiatry.

[5]  A. Hoffman,et al.  Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. , 2003, Journal of medicinal chemistry.

[6]  N. Volkow,et al.  In vivo imaging of the brain cannabinoid receptor. , 2002, Chemistry and physics of lipids.

[7]  J. Brotchie,et al.  Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[8]  J. Herbert,et al.  Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. , 2002, Nuclear medicine and biology.

[9]  H. Emrich,et al.  Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial , 2002 .

[10]  G. Marsicano,et al.  Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain , 2002, Neuroscience.

[11]  J. Brotchie,et al.  Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.

[12]  A. Howlett,et al.  Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum , 2001, Neuropharmacology.

[13]  B. Dean,et al.  Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use , 2001, Neuroscience.

[14]  Vesna Sossi,et al.  Measuring the BP of Four Dopaminergic Tracers Utilizing a Tissue Input Function , 2001 .

[15]  Albert Gjedde,et al.  Physiological imaging of the brain with PET , 2001 .

[16]  R. Dannals,et al.  Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. , 2000, Nuclear medicine and biology.

[17]  J. Brotchie,et al.  Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  D. Sanger,et al.  Pharmacological and molecular targets in the search for novel antipsychotics , 2000, Behavioural pharmacology.

[19]  D. Piomelli,et al.  Reversal of Dopamine D2 Receptor Responses by an Anandamide Transport Inhibitor , 2000, The Journal of Neuroscience.

[20]  Lilli Geworski,et al.  Recovery correction for quantitation in emission tomography: a feasibility study , 2000, European Journal of Nuclear Medicine.

[21]  R. Pertwee.  Cannabis and Cannabinoids: Pharmacology and Rationale for Clinical Use , 1999, Complementary Medicine Research.

[22]  H. Emrich,et al.  Elevated endogenous cannabinoids in schizophrenia. , 1999, Neuroreport.

[23]  Y. Awaad.  Tics in Tourette Syndrome: New Treatment Options , 1999, Journal of Child Neurology.

[24]  G. Curtis,et al.  Treatment of Tourette’s Syndrome With Delta-9-Tetrahydrocannabinol , 1999 .

[25]  N. Volkow,et al.  Large receptor reserve for cannabinoid actions in the central nervous system. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  B. Wessels,et al.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  J. Manzanares,et al.  Time‐course of the cannabinoid receptor down‐regulation in the adult rat brain caused by repeated exposure to Δ9‐tetrahydrocannabinol , 1998, Synapse.

[28]  Payton King,et al.  Imaging the Brain Marijuana Receptor: Development of a Radioligand that Binds to Cannabinoid CB1 Receptors In Vivo , 1998, Journal of neurochemistry.

[29]  Michael G. Stabin,et al.  Human biodistribution and dosimetry of [123I]FP-CIT: a potent radioligand for imaging of dopamine transporters , 1997, European Journal of Nuclear Medicine.

[30]  N. Volkow,et al.  Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices , 1997, Neuroscience Letters.

[31]  F. Markus Leweke,et al.  Towards a Cannabinoid Hypothesis of Schizophrenia: Cognitive Impairments Due to Dysregulation of the Endogenous Cannabinoid System , 1997, Pharmacology Biochemistry and Behavior.

[32]  Guy Marchal,et al.  Multimodality image registration by maximization of mutual information , 1997, IEEE Transactions on Medical Imaging.

[33]  R. Faull,et al.  Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.

[34]  R. Pertwee.  Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[35]  A. Makriyannis,et al.  Preparation of iodine‐123 labeled AM251: A potential SPECT radioligand for the brain cannabinoid CB1 receptor , 1996 .

[36]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  J. Brotchie,et al.  Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus , 1996 .

[38]  N. Volkow,et al.  123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. , 1996, European journal of pharmacology.

[39]  Guy Marchal,et al.  Multi-modality image registration by maximization of mutual information , 1996, Proceedings of the Workshop on Mathematical Methods in Biomedical Image Analysis.

[40]  M G Stabin,et al.  MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[43]  M. Herkenham,et al.  Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study , 1993, Brain Research.

[44]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[45]  A. Wolf,et al.  PET studies in the primate brain and biodistribution in mice using (−)-5′-18 F-Δ 8-THC , 1991, Pharmacology Biochemistry and Behavior.

[46]  G Vassart,et al.  Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.

[47]  L. Deecke,et al.  Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[50]  A. Alavi,et al.  In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[53]  P. Allebeck,et al.  CANNABIS AND SCHIZOPHRENIA , 1988, The Lancet.

[54]  Thomas F. Budinger,et al.  MIRD primer for absorbed dose calculations , 1988 .

[55]  Sven Andréasson,et al.  CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts , 1987, The Lancet.

[56]  E. Dupont,et al.  Progabide in the treatment of hyperkinetic extrapyramidal movement disorders , 1985, Acta neurologica Scandinavica.

[57]  D. Cohen,et al.  A new instrument for clinical studies of Tourette's syndrome. , 1984, Journal of the American Academy of Child Psychiatry.

[58]  Richard B. Firestone,et al.  Table of Isotopes , 1978 .

[59]  W. Wachsmuth,et al.  Prak-tische Anatomie Ein Lehr- und Hilfsbuch der anato-mischen Grundlagen artzlichen Handelns Bd I , 1935 .